Life Sciences

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline
25 March 2024

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing.

Read the press release
Citryll Announces Appointments of Eduardo Bravo as CEO and Tim Schenk as CBO
29 August 2023

Citryll Announces Appointments of Eduardo Bravo as CEO and Tim Schenk as CBO

Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Eduardo...

Read more
Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis
23 May 2023

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

Galecto, Inc., a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today...

Read the press release
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
20 April 2023

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients

Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates...

Read the press release
Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study
5 January 2023

Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study

Domain Therapeutics (“Domain” or “the Company”), a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today...

Read the press release
Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline
25 September 2020

Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline

Galecto., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the successful completion of a $64...

Read more
Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates
21 July 2020

Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates

Tubulis announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates...

Read the press release
MedinCell announces the great success of its capital increase and raises 15.6 M€
17 June 2020

MedinCell announces the great success of its capital increase and raises 15.6 M€

MedinCell (FR0004065605 - MEDCL), a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas (the...

Read more
European Venture Capital Firm Seventure Partners renews its support to Domain Therapeutics and invests €3.5M ($3.9M) to prepare the next growth phase
28 May 2019

European Venture Capital Firm Seventure Partners renews its support to Domain Therapeutics and invests €3.5M ($3.9M) to prepare the next growth phase

Domain Therapeutics announces today that it has secured a €3.5M ($3.9M) investment from existing shareholder Seventure Partners, to accelerate its next growth phase. Since...

Read the press release